Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Study of First Line Pembrolizumab in Combination With Trastuzumab, Capecitabine, and Cisplatin in HER2 Positive Gastric Cancer

X
Trial Profile

A Phase Ib/II Study of First Line Pembrolizumab in Combination With Trastuzumab, Capecitabine, and Cisplatin in HER2 Positive Gastric Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Pembrolizumab (Primary) ; Trastuzumab (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PANTHERA
  • Sponsors Celltrion; Merck Sharp & Dohme
  • Most Recent Events

    • 01 Sep 2023 Results of an analysis monitoring outcomes of systemic chemotherapy using serially collected ctDNA of 15 HER2-positive metastatic GC patients treated with anti-PD-1 inhibitor in combination with standard systemic treatment published in the Yonsei Medical Journal
    • 17 Jan 2021 Results of updated clinical data and molecular profiling results presented at the 2021 Gastrointestinal Cancers Symposium
    • 17 Jan 2021 Results presented at the 2021 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top